Gapping down
In reaction to disappointing earnings/guidance: VMEM -46%, DLIA -22%, TFM -14.3%, LNDC -11.3%, ROST -7.5%, TXTR -3.4%, MENT -2.3%, ANN -2.1%, GPS -0.9%.
Select names showing weakness following offerings: RITT -15.4% ( prices public offerring of ordinary shares and warrants), NAT -11% (announced public offering of ~$65 mln of common shares; CEO expected to purchase ~$2 mln worth of common shares), NTLS -2.9% (announced secondary offering of 1.5 mln shares of common stock by investment funds affiliated with Quadrangle Capital Partners), NLSN -1.7% (announced 30 mln share secondary common stock offering), NHI -0.9% (prices 4.5 mln shares of common stock at $57.00 per share).
Other news: AMRN -15.6% (Co disclosed that it received notification from FDA that it has not accepted for review, on procedural grounds Amarin's appeal for Vascepa review), INTC -2.6% (still checking, could be related to comments from analyst meeting), CLF -1.8% (attributed to peer X dg), TJX -1.5% (in sympathy with peer ROST earnings), .
Analyst comments: MU -0.7% (downgraded to Neutral from Buy at BofA/Merrill), TGT -0.8% (downgraded to Underperform from Neutral at BofA/Merrill), ANF -0.9% (downgraded to Market Perform from Outperform at Wells Fargo), X -1.3% (downgraded to Underperform from Market Perform at Wells Fargo), TTWO -1.7% (downgraded to Market Perform from Outperform at Cowen).